The following is excerpted from the question-and-answer section of the transcript.
(Questions from industry analysts are provided in full, but answers are omitted - download the transcript to see the full question-and-answer session)
Question: Gregory Allen Harrison - BofA Securities, Research Division - Analyst
: Hey, guys. Great presentation today. Very helpful. Thanks for taking our question. We wanted to ask, how broadly do you think that the 502
mechanism can be applied? Could it be developed in additional agitation indications or even beyond -- into some of the others you've talked about
today like stress or anxiety or depression?
Question: Gregory Allen Harrison - BofA Securities, Research Division - Analyst
: Great. And then one just kind of at a broader level with respect to the AI platform, under what circumstances would you consider starting your
own discovery programs to go after some of these targets that the AI platform identifies rather than leveraging existing drugs as you've been
doing?
Question: Sumant Satchidanand Kulkarni - Canaccord Genuity Corp., Research Division - Analyst
: Thanks for all these informative things that you included in your presentation today, I have questions along three lines. The first one is, 501, the
second 502 the third would be a big picture one. On 501 for Dr. Berman or Risinger, how rapidly do you think a product like 501 must act to have
a knock-on effect in depression or does it not matter and what might that mean for trial recruitment and duration of clinical trial to get the best
outcomes and along those lines in clinical practice, do you think anything much change for all of these associated symptoms of depression to be
treated differently by clinicians?
Question: Sumant Satchidanand Kulkarni - Canaccord Genuity Corp., Research Division - Analyst
: And then on 502, can you confirm that molecule is eligible for new chemical entity exclusivity in the US and hatchbacks in Safe Harbor suggest
you're free to develop, but is there anything that might block commercialization of fiber too?
Question: Sumant Satchidanand Kulkarni - Canaccord Genuity Corp., Research Division - Analyst
: My last question is more of a legal and philosophical one. As artificial intelligence evolves, how confident are you that intellectual property generated
by AI won't be considered prior to any AI engines killed in the process?
Question: Anita Dushyanth - Joh. Berenberg, Gossler & Co. KG, Research Division - Analyst
: So just one for me. You've used your AI platform to discover, I guess, 501 and 502 for these symptoms. But although these symptoms -- I mean the
disorders seem seemingly distinct. They do have some underlying similar genes that result in this. So in terms of deciding the strength and frequency
of dose, what factors will you consider when doing that, especially when the symptoms seem to sort of overlap in these psychiatric states?
Question: Anita Dushyanth - Joh. Berenberg, Gossler & Co. KG, Research Division - Analyst
: And then I just had a follow-up. So when you were initially looking at 501, was this one of the relationships with the anxiety, did that show up? Was
that one of the suspects and that kind of confirmed the clinical studies?
| 
